Rheumatology Medical News about anti-rheumatic drugs;rheumatoid arthritis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Life table analysis of treatment episodes with disease-modifying anti-rheumatic drugs in rheumatoid arthritis
Modern Rheumatology, 06/17/09

Nakazaki S et al. – Study reports that the long-term utility of DMARDs therapy for RA was unsatisfying. Methotrexate (MTX) was the most useful, and injectable gold compound (GST), bucillamine (BU), d-penicillamine (DP) and sulfasalazine (SASP) were relatively useful. Relapse of the disease occurred with BU, DP, and SASP.

Methods

An evaluation of the utility of therapy with all the DMARDs in long-term treatment
1666 DMARDs treatment episodes were analyzed using 5-yr life tables

Results

All treatment episodes attributable to DMARDs remained <20% of the pts up to 60 mo
As for the prevalence of pts remaining in the f/u study:
- Those receiving MTX were the most common
- Those receiving injectable gold compound (GST), BU, and DP were higher vs those receiving actalit (ACT) and SASP, and
- Those receiving mizoribine (MZR), lobenzarit (CCA), and auranofin (AF) were least
Treatment terminations for inefficacy in BU, DP, and SASP increased slowly over 36 mo
For all drugs but GST and MTX, the life table curve of terminations for toxicity became horizontal over time
Prevalence of terminations for toxicity in MTX increased even after 48 mo

<< Previous
Analysis of urolithiasis in patients with gout and hyperuricemia...

Next >>
The lifestyle of patients with chronic fatigue syndrome and the...

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09 Relevance Score: 68%

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR)
Annals of Rheumatic Diseases, 11/13/09 Relevance Score: 65%

Early treatment with and time on first Disease Modifying Anti-Rheumatic Drug predicts long-term function in patients with inflammatory polyarthritis
Annals of Rheumatic Diseases, 11/11/09 Relevance Score: 64%

Positive anti-citrullinated protein antibody status and small joint arthritis are consistent predictors of chronic disease in patients with very early arthritis: results from the NOR-VEAC cohort
Arthritis Research & Therapy, 10/02/09 Relevance Score: 62%

Psychotropic Drug Use During Breastfeeding: A Review of the Evidence
Pediatrics, 10/01/09 Relevance Score: 49%